Study of treatments for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests different treatments for people with extensive-stage small cell lung cancer who have not had prior therapy. It aims to find which treatment works best based on the unique features of your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer (cancer that has spread widely in the lung and beyond).
- You have not received any previous treatment for advanced or metastatic disease, or you relapsed after prior radiation and chemotherapy given together for limited-stage disease.
- You are expected to live at least 12 weeks.
- You have at least one measurable tumor that has not been treated with radiation.
- You are well enough to perform daily activities (ECOG score 0 or 1).
- Your blood counts and organ functions (liver, kidneys, heart) meet certain cutoff levels, and you are not pregnant (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
This trial tests combining benmelstobart (a type of immunotherapy), anlotinib (a targeted blood vessel blocker), and standard chemotherapy as the very first treatment for extensive-stage small cell lung cancer (cancer that has spread widely). It aims to see if this combination works better than current options.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests different treatments based on the genetic and molecular features of your tumor. It is for people with stage IV small cell lung cancer that has returned after initial chemotherapy.
This study tests a combination of an oral targeted therapy (anlotinib) with a liposomal form of chemotherapy and an immunotherapy drug as maintenance treatment for extensive-stage small cell lung cancer after initial treatment. It aims to keep the cancer from growing again.
Hear when a new Extensive Stage Lung Small Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.